BioSpace News Archive

Assembly Biosciences, Inc. today announced it has selected a fourth core inhibitor candidate, ABI-4334 (4334), that has been optimized for potency, to advance into clinical development.

TrialJectory (“the Company”), announced today results from a proprietary survey highlighting that, while an overwhelming majority of cancer patients surveyed (90 percent) understand the importance of genetic testing for achieving better clinical outcomes, less than half (46 percent) reported having undergone Next-Generation Sequencing (NGS),

The reports at TMR Research provide qualitative solutions that break the barriers of doubt or uncertainties when the stakeholders plan to expand their growth reach.

Common warts, or cutaneous warts, are abnormal epithelial growth in the skin and mucous membrane. Common warts are known to be caused by the Human Papilloma Virus (HPV).

Fact.MR – A Market Research and Competitive Intelligence Provider: Various invasive medical procedures are susceptible to excessive blood loss, especially cesarean deliveries and major organ surgeries.

A wide range of assistive listening devices act as hearing aids to help individuals improve the communication of individuals with hearing loss.

Growing focus of major population from all across the world to improve their aesthetics is working as one of the key drivers for the development of the global alexandrite laser treatment market.

Alligator Bioscience announced that the company has entered into a research collaboration and license agreement with Orion Corporation, a global pharmaceutical company based in Finland, to discover and develop together new bispecific antibody cancer therapeutics

Cinclus Pharma Holding AB, a biopharmaceutical company focused on the development of a novel treatment for severe gastroesophageal reflux disease, announced that the first patient has been randomized in the Phase II dose ranging study for its lead candidate drug X842.

HistoIndex, a global leading artificial intelligence (AI) digital pathology provider, has announced an agreement with clinical-stage biotechnology company Sagimet Biosciences.